4 June 2025 | 12:29PM EDT Sagimet Biosciences (SGMT): Ph3 Ascletis-partnered trial confirms denifanstat's therapeutic profile in acne SGMT's partner Ascletis (covered by Ziyi Chen) announced positive topline results from its Ph3 trial of denifanstat in patients with moderate to severe acne. Part of a joint-development program between SGMT/Ascletis, the study evaluated denifanstat's efficacy and safety in 480 patients treated with either denifanstat 50mg (QD, oral) or matching placebo for 12 weeks and found ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. SAN MATEO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel the ...

Sagimet Biosciences (SGMT) Update / Briefing May 29, 2025 01:00 PM ET Speaker0 Greetings, and welcome to the Sagimet Biosciences Post EASL Key Opinion Leader Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentations. As a reminder, this conference is being recorded. Before we begin, I would like to remind our listeners that our comments today will include some forward looking statements. These statements include statements regarding th ...

SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET. To register, click here. The event will feature Rohit Loomba, MD, MHSc (Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Ce ...

Exhibit 99.2 Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer May 2025 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to pre: conditions, including but not limited to, statements regarding possible or assumed fu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41742 Sagimet Biosciences Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

SAN MATEO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates. “Sagimet is committed to bringing innovative therapies to MASH patients, following the successful results of our Phase 2b FASCINATE-2 clinical trial of denifanstat in MASH F2-F3 p ...

SAN MATEO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that three poster presentations featuring additional analyses from the Phase 2b FASCINATE-2 study of denifanstat in MASH will be presented at the European Association for the Study of Liver (EASL) Congress 2025 being held May 7-10, 2025 in Amsterdam, Netherlands ...

Financial Performance - Sagimet reported a net loss of $45.6 million for the full year ended December 31, 2024, compared to a net loss of $27.9 million for the previous year, representing a 63.5% increase in losses[11]. - Research and development expenses for the year were $38.4 million, up from $19.8 million in 2023, indicating a 93.1% increase year-over-year[11]. - Cash, cash equivalents, and marketable securities as of December 31, 2024, were $158.7 million, expected to fund operations for at least the next 12 months[11]. - Cash, cash equivalents, and marketable securities increased to $158,658 million in December 2024 from $94,897 million in December 2023, representing a growth of 67.5% [20]. - Total assets rose to $160,259 million in December 2024, up from $96,719 million in December 2023, indicating a growth of 65.7% [20]. - Current liabilities decreased to $4,454 million in December 2024 from $5,654 million in December 2023, reflecting a reduction of 21.1% [20]. - Stockholders' equity increased significantly to $155,805 million in December 2024, compared to $91,065 million in December 2023, marking a growth of 71.1% [20]. - Liabilities and stockholders' equity totaled $160,259 million in December 2024, consistent with total assets, indicating a balanced financial position [20]. Clinical Development - The company initiated its Phase 3 denifanstat program in metabolic dysfunction-associated steatohepatitis (MASH) in Q4 2024, with patient screening expected to start in the first half of 2025[11]. - Sagimet received Breakthrough Therapy designation from the FDA for denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis in October 2024[7]. - The Phase 3 program for denifanstat will include two trials, FASCINATE-3 and FASCINIT, with a minimum of 1,800 patients expected to be exposed to denifanstat[11]. - The Phase 2b FASCINATE-2 trial of denifanstat met its primary efficacy endpoints, demonstrating significant improvements in disease activity and fibrosis[7]. - The company plans to seek accelerated approval for denifanstat based on 52-week data from the FASCINATE-3 trial[11]. - Sagimet announced the clearance of its IND application for TVB-3567, a second FASN inhibitor, for the treatment of acne, with a Phase 1 trial anticipated to start in 2025[4]. Financing Activities - The company completed a follow-on offering of 9,000,000 shares in January 2024, resulting in net proceeds of $104.7 million[8].